Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.71 and traded as high as $2.33. Adaptimmune Therapeutics shares last traded at $2.32, with a volume of 515,641 shares.
Adaptimmune Therapeutics Stock Performance
The business has a 50-day moving average price of $1.73 and a 200 day moving average price of $2.03.
Get
Adaptimmune Therapeutics alerts:
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last released its earnings results on Monday, May 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). The business had revenue of $3.58 million during the quarter, compared to analysts' expectations of $4.00 million. Adaptimmune Therapeutics had a negative net margin of 1,500.43% and a negative return on equity of 86.57%. During the same quarter in the previous year, the company earned ($0.24) EPS. Sell-side analysts forecast that Adaptimmune Therapeutics plc will post -1.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Inspire Investing LLC acquired a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth approximately $58,000. Daiwa Securities Group Inc. increased its holdings in shares of Adaptimmune Therapeutics by 59.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 24,515 shares of the biotechnology company's stock valued at $92,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Adaptimmune Therapeutics by 13.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 69,140 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 8,292 shares in the last quarter. Syncona Portfolio Ltd acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $5,165,000. Finally, DAFNA Capital Management LLC acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $511,000.
Adaptimmune Therapeutics Company Profile
(Get Rating)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Featured Stories
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.71 and traded as high as $2.33. Adaptimmune Therapeutics shares last traded at $2.32, with a volume of 515,641 shares.
在周四的交易中，Adaptimmune Treateutics公司(纳斯达克代码：ADAP-GET Rating)的股价超过了50日移动均线。该股的50日移动均线为1.71美元，交易价格高达2.33美元。Adaptimmune Treateutics的股票最后交易价格为2.32美元，成交量为515,641股。
Adaptimmune Therapeutics Stock Performance
Adaptimmune Treateutics股票表现
The business has a 50-day moving average price of $1.73 and a 200 day moving average price of $2.03.
该业务的50日移动均线价格为1.73美元，200日移动均线价格为2.03美元。
Get
Adaptimmune Therapeutics
alerts:
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last released its earnings results on Monday, May 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). The business had revenue of $3.58 million during the quarter, compared to analysts' expectations of $4.00 million. Adaptimmune Therapeutics had a negative net margin of 1,500.43% and a negative return on equity of 86.57%. During the same quarter in the previous year, the company earned ($0.24) EPS. Sell-side analysts forecast that Adaptimmune Therapeutics plc will post -1.18 earnings per share for the current fiscal year.
自适应免疫治疗公司(纳斯达克代码：ADAP-GET评级)最近一次公布收益结果是在5月9日星期一。这家生物技术公司公布的季度每股收益(EPS)为0.32美元，低于分析师普遍预期的0.26美元和0.06美元。该业务本季度营收为358万美元，高于分析师预期的400万美元。Adaptimmune Treeutics的净利润率为负1,500.43%，净资产回报率为负86.57%。去年同期，该公司每股收益为0.24美元。卖方分析师预测，Adaptimmune Treateutics plc本财年每股收益将达到1.18美元。
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Inspire Investing LLC acquired a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth approximately $58,000. Daiwa Securities Group Inc. increased its holdings in shares of Adaptimmune Therapeutics by 59.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 24,515 shares of the biotechnology company's stock valued at $92,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Adaptimmune Therapeutics by 13.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 69,140 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 8,292 shares in the last quarter. Syncona Portfolio Ltd acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $5,165,000. Finally, DAFNA Capital Management LLC acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $511,000.
一些对冲基金和其他机构投资者最近增持或减持了该业务的股份。Inspire Investment LLC在第四季度收购了Adaptimmune Treeutics的新股份，价值约5.8万美元。第四季度，大和证券集团增持Adaptimmune Treeutics股票59.4%。大和证券集团(Daiwa Securities Group Inc.)目前持有这家生物技术公司24,515股股票，价值92,000美元，上个季度又购买了9,133股。三菱日联国材资产管理株式会社第四季增持Adaptimmune Treeutics股票13.6%。三菱UFJ国赛资产管理有限公司在上个季度增持了8,292股后，现在持有69,140股这家生物技术公司的股票，价值28.1万美元。Syncona Portfolio Ltd在第四季度收购了Adaptimmune Treeutics的新股份，价值约5,165,000美元。最后，Dafna Capital Management LLC在第四季度收购了Adaptimmune Treateutics的新股份，价值约511,000美元。
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Adaptimmune Treateutics公司是一家临床阶段的生物制药公司，主要为美国和英国的实体肿瘤患者提供新型细胞疗法。该公司的特定多肽增强亲和力受体(SPEAR)T细胞平台使其能够识别癌症靶点。
Featured Stories
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免费获取StockNews.com关于Adaptimmune治疗(ADAP)的研究报告
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- 苹果为何可能在年底创下历史新高
- Beyond Meat不是没有希望，而且它很便宜
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《适应性免疫治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Adaptimmune Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
